CUSTOM IV

Using data generated by our CUSTOM I, II and III clinical trials, we submitted an Investigational Device Exemption (IDE) to the FDA and expect to initiate our U.S. pivotal clinical trial, CUSTOM IV, in 2008. CUSTOM IV will evaluate XTENT^® Custom NX^® DES Systems against a marketed drug eluting stent for the treatment of CAD.